U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Drugs
  3. Development & Approval Process | Drugs
  4. Drug Development Tool (DDT) Qualification Programs
  5. Clinical Outcome Assessment (COA) Qualification Program
  6. DDT COA #000056: Varicose Vein Symptom Questionnaire (VVSymQ)
  1. Clinical Outcome Assessment (COA) Qualification Program

DDT COA #000056: Varicose Vein Symptom Questionnaire (VVSymQ)

Clinical Outcome Assessments (COA) Qualification Submissions
Office of Cardiology, Hematology, Endocrinology, and Nephrology (OCHEN)
Division of Cardiovascular and Nephrology (DCN)

DDT COA Number
DDT COA #000056

Instrument Name
Varicose Vein Symptom Questionnaire (VVSymQ)

Disease/Condition
Varicose Veins

Concept of Interest
Varicose vein symptoms

Context of Use
Patients with superficial venous incompetence

COA Type
PRO

Qualification Stage
In legacy process*

Requestor(s)
BTG International, Inc

Contact(s)
Simon Leppard

Date Accepted into CDER’s COA Qualification Program
May 13, 2014

 

*Under review prior to the passage of the 21st Century Cures Act

Back to Top